Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis: Do the Benefits Outweigh the Harms?

Am J Respir Crit Care Med. 2018 Nov 15;198(10):1348-1349. doi: 10.1164/rccm.201807-1329LE.

Authors

Shivanthan Shanthikumar^{1

2

3}, Colin Robertson^{1

2

3}, Sarath Ranganathan^{1

2

3}

Affiliations

¹ 1 Royal Children's Hospital Melbourne, Australia.
² 2 Murdoch Children's Research Institute Melbourne, Australia and.
³ 3 The University of Melbourne Melbourne, Australia.

PMID: 30138568
DOI: 10.1164/rccm.201807-1329LE

No abstract available

Publication types

Letter
Comment

MeSH terms

Anti-Bacterial Agents
Azithromycin
Cystic Fibrosis*
Humans
Pseudomonas Infections*
Pseudomonas aeruginosa

Substances

Anti-Bacterial Agents
Azithromycin